Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Minority Interest (2022 - 2025)

Oramed Pharmaceuticals' Minority Interest history spans 4 years, with the latest figure at -$952000.0 for Q3 2025.

  • For Q3 2025, Minority Interest fell 3.59% year-over-year to -$952000.0; the TTM value through Sep 2025 reached -$952000.0, down 3.59%, while the annual FY2023 figure was -$928000.0, 41.46% down from the prior year.
  • Minority Interest reached -$952000.0 in Q3 2025 per ORMP's latest filing, down from -$946000.0 in the prior quarter.
  • In the past five years, Minority Interest ranged from a high of -$126000.0 in Q1 2022 to a low of -$952000.0 in Q3 2025.
  • Average Minority Interest over 4 years is -$800714.3, with a median of -$906500.0 recorded in 2023.
  • Peak YoY movement for Minority Interest: crashed 552.38% in 2023, then changed 0.0% in 2025.
  • A 4-year view of Minority Interest shows it stood at -$656000.0 in 2022, then crashed by 41.46% to -$928000.0 in 2023, then grew by 0.97% to -$919000.0 in 2024, then fell by 3.59% to -$952000.0 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Minority Interest are -$952000.0 (Q3 2025), -$946000.0 (Q2 2025), and -$918000.0 (Q1 2025).